DMG MORI AKTIENGESELLSCHAFT

  • WKN: 587800
  • ISIN: DE0005878003
  • Land: Deutschland

Nachricht vom 14.03.2016 | 21:00

DMG MORI AKTIENGESELLSCHAFT: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements


DMG MORI AKTIENGESELLSCHAFT  / Preliminary announcement on the
disclosure of financial statements

14.03.2016 21:00

Preliminary announcement of the publication of quarterly reports and
quarterly/interim statements, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DMG MORI AKTIENGESELLSCHAFT hereby announces that the following financial reports shall be disclosed : Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / German: April 26, 2016 Date of disclosure / English: April 26, 2016 German: https://downloads.dmgmori.com/5846247731/dmgmori116d.pdf English: https://downloads.dmgmori.com/9147237458/dmgmori116e.pdf Report: Quarterly financial report within the 2nd half-year (Q3) Date of disclosure / German: October 27, 2016 Date of disclosure / English: October 27, 2016 German: https://downloads.dmgmori.com/7344824751/dmgmori316d.pdf English: https://downloads.dmgmori.com/4875321921/dmgmori316e.pdf 14.03.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: DMG MORI AKTIENGESELLSCHAFT Gildemeisterstraße 60 33689 Bielefeld Germany Internet: www.dmgmoriseiki.com End of Announcement DGAP News-Service

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021